Chronic Paediatric Conditions

On this page

Epidemiology and Core Definitions: Understanding the Burden

A 7-year-old girl presents with polyuria and weight loss; across the corridor, a 5-year-old boy has just experienced his second unprovoked seizure. These scenarios represent two of the most prevalent chronic conditions in paediatric medicine. affects approximately 215,000 children under 15 years globally, with UK incidence rising at 3-4% annually. has even greater reach, affecting 1 in 200 children, making it the most common serious neurological condition in paediatrics. Understanding their epidemiology shapes service provision, family support, and long-term outcome planning.

  • Type 1 Diabetes (T1D): Autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency

    • UK incidence: 24.5 per 100,000 children annually
    • Peak presentation ages: 4-6 years and 10-14 years
    • Accounts for >95% of childhood diabetes cases
    • Male:female ratio approximately 1:1
  • Epilepsy: Recurrent tendency to unprovoked seizures (≥2 unprovoked seizures >24 hours apart, or 1 seizure with high recurrence risk)

    • UK prevalence: 5-10 per 1,000 children
    • 70% diagnosed before age 20 years
    • Idiopathic epilepsy accounts for 60-65% of cases
    • Mortality rate: 1.2 per 1,000 person-years (general population: 0.1)
ParameterType 1 DiabetesEpilepsy
UK Prevalence2 per 1,000 children5-10 per 1,000 children
Annual Incidence24.5 per 100,00060 per 100,000
Median Age at Diagnosis10-14 years5-6 years
Male:Female Ratio1:11.2:1

📌 Mnemonic for T1D Presentation: The 4 T's - Toilet (polyuria), Thirsy (polydipsia), Tired (lethargy), Thinner (weight loss)

Figure 1: Fundoscopy showing early diabetic retinopathy with microaneurysms and dot hemorrhages

Epidemiology and Core Definitions: Understanding the Burden

Pathophysiological Mechanisms: From Molecular to Clinical

The pathogenesis of involves genetic susceptibility (HLA-DR3/DR4 haplotypes confer 50% risk), environmental triggers (viral infections, dietary factors), and immune dysregulation leading to insulitis. β-cell destruction occurs over months to years, with clinical presentation when 80-90% are destroyed. In contrast, represents diverse mechanisms: ion channelopathies (SCN1A mutations in Dravet syndrome), structural abnormalities (cortical dysplasia), or acquired insults (hypoxic-ischemic injury). The final common pathway is neuronal hyperexcitability from imbalance between excitatory (glutamate) and inhibitory (GABA) neurotransmission.

  • T1D Pathophysiology:

    • Autoantibodies: GAD, IA-2, ZnT8 (present in 85-90% at diagnosis)
    • Progressive β-cell loss → impaired first-phase insulin response → postprandial hyperglycemia
    • Absolute insulin deficiency → lipolysis → ketogenesis → DKA risk
    • Counter-regulatory hormone excess (glucagon, cortisol, catecholamines) exacerbates hyperglycemia
  • Epilepsy Pathophysiology:

    • Genetic: Ion channel mutations (Na⁺, K⁺, Ca²⁺ channels) alter neuronal excitability
    • Structural: Hippocampal sclerosis, focal cortical dysplasia create epileptogenic foci
    • Metabolic: Glucose transporter defects (GLUT1 deficiency) impair neuronal energy
    • Acquired: Febrile seizures, head trauma, CNS infections trigger epileptogenesis
MechanismType 1 DiabetesEpilepsy
Primary DefectAutoimmune β-cell destructionNeuronal hyperexcitability
Key MoleculesInsulin, C-peptide, autoantibodiesGlutamate, GABA, ion channels
Onset PatternSubacute (weeks-months)Variable (acute to chronic)
ReversibilityIrreversiblePotentially reversible (60-70%)

Figure 2: EEG showing generalized 3Hz spike-and-wave pattern characteristic of childhood absence epilepsy

Pathophysiological Mechanisms: From Molecular to Clinical

Clinical Application: Diagnosis and Initial Management

A 9-year-old presents with 3-week history of excessive thirst, nocturia, and 4kg weight loss. Random glucose is 18.2 mmol/L; venous pH 7.32, ketones 3.8 mmol/L. NICE NG18 guides immediate management: confirm diabetes (HbA1c ≥48 mmol/mol or fasting glucose ≥7.0 mmol/L), assess for DKA (pH <7.3 or bicarbonate <15 mmol/L), and initiate insulin therapy within 24 hours. Meanwhile, a 6-year-old experiences a 90-second episode of staring, unresponsiveness, and lip-smacking. Witnessed second episode 3 weeks later. NICE NG217 recommends specialist assessment within 2 weeks for first unprovoked seizure, EEG within 4 weeks, and neuroimaging (MRI preferred) to identify structural causes.

  • T1D Diagnostic Criteria (WHO):

    • Symptoms + random glucose ≥11.1 mmol/L, OR
    • Fasting glucose ≥7.0 mmol/L (no caloric intake 8 hours), OR
    • HbA1c ≥48 mmol/mol (≥6.5%)
    • C-peptide <200 pmol/L confirms insulin deficiency
  • DKA Assessment (NICE NG18):

    • Hyperglycemia (glucose >11 mmol/L)
    • Ketonemia (β-hydroxybutyrate >3.0 mmol/L) or ketonuria (2+ on dipstick)
    • Acidosis (pH <7.3 or bicarbonate <15 mmol/L)
    • Severity: Mild (pH 7.2-7.29), Moderate (pH 7.1-7.19), Severe (pH <7.1)
  • Epilepsy Diagnosis (NICE NG217):

    • Clinical: ≥2 unprovoked seizures >24 hours apart, OR
    • 1 seizure + EEG showing epileptiform activity + structural abnormality
    • EEG sensitivity: 50% after first seizure, 80-90% after multiple recordings
    • MRI brain: identifies structural causes in 15-20% (cortical dysplasia, tumors, vascular malformations)
InvestigationType 1 DiabetesEpilepsy
First-lineRandom/fasting glucose, HbA1cEEG (awake and sleep)
ConfirmatoryC-peptide, autoantibodiesVideo-EEG telemetry
ImagingNot routine (consider if atypical)MRI brain (all first seizures)
TimeframeSame-day assessmentSpecialist within 2 weeks

🚩 Red Flag: In suspected DKA, never give insulin bolus without IV fluids first-risks cerebral edema from rapid osmotic shifts.

Figure 3: CT brain showing focal cortical dysplasia in right frontal lobe with blurred grey-white matter junction

Comparative Analysis: Distinguishing Features and Pitfalls

Both conditions present diagnostic challenges. New-onset T1D can mimic urinary tract infection (polyuria), eating disorders (weight loss), or behavioral problems (irritability). Key discriminator: random glucose >11.1 mmol/L is diagnostic; urinalysis showing glycosuria without infection confirms suspicion. Epilepsy diagnosis requires distinguishing seizures from syncope (gradual vs. sudden onset, prolonged vs. brief loss of consciousness), breath-holding spells (cyanosis, triggered by distress), or parasomnias (occur from sleep, stereotyped movements). EEG epileptiform discharges (sensitivity 50% first recording, 80-90% with repeat sleep-deprived studies) provide objective evidence, but normal EEG doesn't exclude epilepsy-diagnosis remains clinical.

  • T1D Differential Diagnosis:

    • Type 2 diabetes: Older age, obesity, acanthosis nigricans, family history
    • Monogenic diabetes (MODY): Family history, non-obese, GAD antibody-negative
    • Stress hyperglycemia: Resolves with illness resolution, HbA1c normal
    • Diabetes insipidus: Polyuria without hyperglycemia, low urine osmolality
  • Epilepsy Differential Diagnosis:

    • Syncope: Prodrome (lightheadedness), pallor, brief duration (<30 seconds), rapid recovery
    • Psychogenic non-epileptic seizures: Eyes closed during event, prolonged duration, no postictal confusion
    • Migraine with aura: Visual symptoms, gradual spread, followed by headache
    • Parasomnias: Occur exclusively from sleep, no daytime events
FeatureSeizureSyncope
OnsetSudden, no warningGradual, prodrome common
Duration1-3 minutes<30 seconds
Color ChangeCyanosis possiblePallor typical
Postictal StateConfusion 5-15 minutesRapid full recovery
Injury RiskHigh (falls, tongue-biting)Lower (gradual collapse)

Clinical Pearl: C-peptide <200 pmol/L distinguishes T1D from T2D (preserved in T2D). In epilepsy, prolactin rises 10-20 minutes post-seizure (not in psychogenic seizures), but short half-life limits clinical utility.

Evidence-Based Management: Treatment Protocols and Monitoring

NICE NG18 mandates multiple daily injection (MDI) regimen or continuous subcutaneous insulin infusion (CSII/pump) for all children with T1D. Initial total daily dose: 0.5-1.0 units/kg/day, split 50% basal (once-daily long-acting analog: glargine, detemir, degludec) and 50% bolus (rapid-acting analog: lispro, aspart, glulisine) with meals using carbohydrate counting (1 unit per 10-15g carbohydrate). Target HbA1c ≤48 mmol/mol without disabling hypoglycemia. Continuous glucose monitoring (CGM) or flash glucose monitoring recommended for all. management follows NICE NG217: first-line monotherapy based on seizure type-sodium valproate for generalized seizures (contraindicated in females of childbearing potential due to teratogenicity), carbamazepine or lamotrigine for focal seizures. Start low, titrate slowly to minimize adverse effects. Target: seizure freedom with minimal side effects. Aim for monotherapy; if ineffective after 2 appropriate trials, refer to tertiary epilepsy center.

  • T1D Insulin Regimens:

    • MDI: Basal-bolus (e.g., glargine 0.3 units/kg once daily + aspart 0.15 units/kg per meal)
    • CSII: Basal rate 0.4-0.6 units/kg/day, bolus calculator based on carb ratio and correction factor
    • Sick day rules: Continue basal, increase monitoring, check ketones if glucose >14 mmol/L
  • Epilepsy First-Line Medications (NICE NG217):

    • Focal seizures: Carbamazepine (10-20 mg/kg/day divided BID), lamotrigine (1-5 mg/kg/day)
    • Generalized tonic-clonic: Sodium valproate (20-30 mg/kg/day divided BID), lamotrigine
    • Absence seizures: Ethosuximide (20 mg/kg/day divided BID), sodium valproate
    • Myoclonic seizures: Sodium valproate, levetiracetam (20-40 mg/kg/day divided BID)
MedicationStarting DoseTarget DoseKey Adverse Effects
Carbamazepine5 mg/kg/day10-20 mg/kg/dayRash, hyponatremia, diplopia
Lamotrigine0.5 mg/kg/day1-5 mg/kg/dayStevens-Johnson syndrome (slow titration essential)
Sodium Valproate10 mg/kg/day20-30 mg/kg/dayWeight gain, tremor, teratogenicity
Levetiracetam10 mg/kg/day20-40 mg/kg/dayBehavioral changes, somnolence

⚠️ Warning: Never abruptly stop anti-epileptic drugs-risks rebound seizures and status epilepticus. Taper over 2-3 months minimum.

Evidence-Based Management: Treatment Protocols and Monitoring

Advanced Integration: Complex Cases and Special Considerations

A 14-year-old with T1D presents with recurrent severe hypoglycemia (glucose <3.0 mmol/L) despite optimized insulin regimen. Investigations reveal hypoglycemia unawareness (loss of autonomic warning symptoms) and impaired counter-regulatory response. Management requires technology integration: emphasizes hybrid closed-loop systems (automated insulin delivery adjusted by CGM readings) reducing hypoglycemia by 40% versus standard therapy. Simultaneously, structured education addressing hypoglycemia fear and glucose variability is essential. In epilepsy, drug-resistant epilepsy (failure of 2 appropriate medications) affects 30% of children. guidelines recommend early tertiary referral for video-EEG telemetry, advanced neuroimaging (3T MRI with epilepsy protocol), and consideration of epilepsy surgery (temporal lobectomy achieves 60-80% seizure freedom in mesial temporal sclerosis), vagal nerve stimulation, or ketogenic diet (50% responder rate in drug-resistant cases).

  • T1D Special Populations:

    • Adolescents: HbA1c typically 10-15 mmol/mol higher due to insulin resistance, autonomy challenges
    • Exercise: Reduce bolus insulin 30-50% before activity, consume 15-30g carbohydrate per hour
    • Sick days: Never omit insulin; increase monitoring to 2-4 hourly; seek help if persistent ketones >1.5 mmol/L
  • Epilepsy Complications:

    • SUDEP (Sudden Unexpected Death in Epilepsy): Risk 1:4,500 child-years; higher with uncontrolled generalized tonic-clonic seizures
    • Status epilepticus: Seizure >5 minutes requires buccal midazolam 0.5 mg/kg (max 10 mg) or rectal diazepam 0.5 mg/kg
    • Cognitive impact: 30-40% have comorbid learning difficulties; screen annually
ComplicationType 1 DiabetesEpilepsy
Acute Life-ThreateningDKA (1-2% annual risk)Status epilepticus (5% lifetime risk)
Chronic MorbidityRetinopathy, nephropathy (rare <10 years)Cognitive impairment (30-40%)
Mortality0.1-0.2 per 1,000 person-years1.2 per 1,000 person-years
Quality of Life ImpactHigh (daily management burden)Moderate (driving restrictions, injury risk)

💎 Clinical Pearl: In drug-resistant epilepsy, early surgical evaluation is critical-outcomes are best when surgery occurs within 2 years of diagnosis, before secondary generalization develops.

Advanced Integration: Complex Cases and Special Considerations

High Yield Summary

Key Take-Aways:

  • T1D requires same-day specialist assessment; target HbA1c ≤48 mmol/mol with MDI or CSII using CGM for all children
  • DKA management: IV fluids first (10 mL/kg 0.9% saline), then insulin 0.05-0.1 units/kg/hour; never bolus insulin
  • Epilepsy diagnosis is clinical; EEG supports but normal EEG doesn't exclude diagnosis (50% sensitivity first recording)
  • First-line epilepsy treatment: carbamazepine/lamotrigine for focal seizures; valproate for generalized (avoid in females)
  • Drug-resistant epilepsy (30% of cases) requires tertiary referral after 2 failed appropriate medications for surgical evaluation
  • SUDEP risk 1:4,500 child-years; highest with uncontrolled generalized tonic-clonic seizures
  • Status epilepticus (seizure >5 minutes) requires immediate buccal midazolam 0.5 mg/kg or rectal diazepam 0.5 mg/kg

Essential Chronic Paediatric Conditions Numbers:

ParameterValueClinical Significance
T1D HbA1c Target≤48 mmol/molBalance glycemic control with hypoglycemia risk
DKA DefinitionpH <7.3 + ketones >3.0 mmol/LRequires immediate hospital admission
Hypoglycemia Threshold<3.0 mmol/LTreat with 15g fast-acting carbohydrate
Epilepsy Drug Failure2 appropriate trialsDefines drug-resistant epilepsy
Status EpilepticusSeizure >5 minutesEmergency requiring benzodiazepine
SUDEP Risk1:4,500 child-yearsCounsel families on seizure control importance

Key Principles:

  • Technology transforms T1D management: hybrid closed-loop systems reduce hypoglycemia 40% versus MDI
  • Never stop anti-epileptic drugs abruptly-taper over minimum 2-3 months to prevent rebound seizures
  • C-peptide <200 pmol/L confirms T1D; distinguishes from T2D where C-peptide preserved
  • Sodium valproate contraindicated in females of childbearing potential due to teratogenicity (neural tube defects 1-2%)
  • Epilepsy surgery achieves 60-80% seizure freedom in appropriate candidates; best outcomes when performed early

Quick Reference:

ConditionEmergency ManagementMonitoringLong-term Target
T1D DKA10 mL/kg 0.9% saline, then insulin 0.05-0.1 units/kg/hrHourly glucose, 2-hourly venous gasResolution: pH >7.3, ketones <0.6 mmol/L
Hypoglycemia15g glucose, repeat in 15 min if neededCGM/flash monitoringTime in range 70-180 mg/dL >70%
Status EpilepticusBuccal midazolam 0.5 mg/kg (max 10 mg)Seizure diary, medication adherenceSeizure freedom
Drug-Resistant EpilepsyTertiary referral after 2 failed medicationsVideo-EEG telemetry, 3T MRIConsider surgery/VNS/ketogenic diet

Practice Questions: Chronic Paediatric Conditions

Test your understanding with these related questions

A 8-year-old child presents with fever, irritability, and a widespread petechial rash that doesn't blanch with pressure. The child appears unwell and has neck stiffness. What is the most appropriate immediate management?

1 of 5

Flashcards: Chronic Paediatric Conditions

1/9

Down's syndrome is managed by a _____ whose care is normally coordinated by a community or neurodisability paediatrician

TAP TO REVEAL ANSWER

Down's syndrome is managed by a _____ whose care is normally coordinated by a community or neurodisability paediatrician

MDT

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial